Table 3.
Correlation between mutation of TRβ1 and clinicopathological features of breast cancer patients
| Clinicopathological features | Patients (n) | Mutation, n (%) | χ2 | P-value |
|---|---|---|---|---|
| Age (years) | ||||
| >50 | 49 | 7 (14.28%) | 1.351 | 0.245 |
| ≤50 | 56 | 13 (23.21%) | ||
| Tumor stage | ||||
| Stage II | 45 | 13 (28.89%) | 0.623 | 0.430 |
| Stage III, stage IV | 60 | 7 (11.67%) | ||
| Menopausal status | ||||
| Pre | 46 | 15 (32.61%) | 9.764 | 0.002 |
| Post | 59 | 5 (8.474%) | ||
| ER status | ||||
| Positive | 42 | 4 (9.52%) | 4.118 | 0.042 |
| Negative | 63 | 16 (25.39%) | ||
Abbreviations: ER, estrogen receptor; TRβ1, thyroid hormone receptor β1.